Product Description
Mechanisms of Action: Fatty Acid Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pronova BioPharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dyslipidemia|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic
Phase 1: Healthy Volunteers|Dyslipidemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NST-01 | P1 |
Completed |
Dyslipidemia |
2018-09-15 |
60% |
2024-11-27 |
Primary Endpoints|Treatments |
| CTN401614104 | P1 |
Completed |
Healthy Volunteers |
2015-08-01 |
2019-03-20 |
Treatments |
|
| CTN401614103 | P1 |
Completed |
Healthy Volunteers |
2014-10-01 |
2019-03-20 |
Treatments |
|
| CTN401614102 | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
2019-03-20 |
Treatments |
|
| ICONA | P2 |
Completed |
Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic |
2022-02-20 |
67% |
2023-03-09 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| CTN 4016 13202 | P2 |
Terminated |
Dyslipidemia |
2014-07-01 |
2019-03-20 |
Treatments |
|
| CTN 4016 13201 | P2 |
Completed |
Dyslipidemia |
2014-07-01 |
2019-03-19 |
Treatments |